

Clinical Management Review

Cigarette Smoking and Asthma

Neil C. Thomson, MD^a, Riccardo Polosa, MD^{b,c,d}, and Don D. Sin, MD^e *Glasgow, United Kingdom; Catania, Italy; and Vancouver, BC, Canada*

Globally, around half the adult asthma population are current or former cigarette smokers. Cigarette smoking and asthma interact to induce an “asthma-smoking phenotype(s),” which has important implications for diagnosis, pathogenic mechanisms, and management. The lack of progress in understanding the effects of smoking on adults with asthma is due in part to their exclusion from most investigative studies and large clinical trials. In this review, we summarize the adverse clinical outcomes associated with cigarette smoking in asthma, highlight challenges in diagnosing asthma among cigarette smokers with chronic respiratory symptoms, particularly in older individuals with a long-standing smoking history, and review pathogenic mechanisms involving smoking- and asthma-related airway inflammation, tissue remodeling, corticosteroid insensitivity, and low-grade systemic inflammation. We discuss the key components of management including the importance of smoking cessation strategies, evidence for the effectiveness of the Global Initiative for Asthma recommendations on treatment in cigarette smokers, and the role of treatable traits such as type 2 eosinophilic airway inflammation. Lastly, we provide an algorithm to aid clinicians to manage current and former smokers with asthma. In the future, controlled and pragmatic trials in real-world populations should include cigarette smokers with asthma to provide an evidence base for treatment recommendations. © 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>). (J Allergy Clin Immunol Pract 2022;■:■-■)

Key words: Asthma; Asthma–chronic obstructive pulmonary disease overlap; Chronic obstructive pulmonary disease; Cigarette smoking; Smokers with asthma; Smoking cessation

Nearly 1 billion people globally are tobacco smokers.¹ Although its prevalence is projected to decrease over the next decade, the total number of smokers will remain high because of population growth. In 2020, men had a much higher prevalence of cigarette smoking than women, 26% and 5%, respectively, which was particularly evident among men living in the World Health Organization (WHO) Western Pacific region of the world (42%), largely reflecting data from China, and the European region (30%).¹ A WHO survey undertaken in the early 2000s showed that the proportion of current smokers with asthma was no different from the general population.² Current smoking rates are higher among some asthma subgroups, such as adults attending US emergency departments with an exacerbation, where over one-third were smokers.³ International severe asthma registry data have shown a low prevalence of current smoking (<10%),⁴ although higher smoking rates were found among patients with severe asthma in primary care.⁵ The prevalence of former smoking in asthma ranges from around one-quarter⁶ to over 40%.^{5,7} Globally, cigarette smoking has an adverse impact on disability-adjusted life years of people with asthma, particularly in men and among those living in Europe, Western Pacific nations, and Southeast Asia.⁸ Collectively, these findings indicate that around 50% of adults with asthma give a history of current or former cigarette smoking and that cigarette smoking contributes to the worldwide health burden of asthma.

^aInstitute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

^bDepartment of Clinical & Experimental Medicine, University of Catania, Catania, Italy

^cCentre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital “Policlinico-V. Emanuele”, University of Catania, Catania, Italy

^dCenter of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy

^eDivision of Respiratory, Department of Medicine, Centre for Heart Lung Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada
R. Polosa was supported by the University of Catania (Italy) and D. D. Sin was supported by a Canada Research Chair Award and the de Lazzari Family Chair at the Centre of Heart Lung Innovation (HLI).

Conflicts of interest: R. Polosa is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same university. He has received grants from U-BIOPRED and AIRPROM, Integral Rheumatology & Immunology Specialists Network (IRIS), Foundation for a Smoke Free World, Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl., Duska Therapeutics, and Forest Laboratories. He is the founder of the Center for Tobacco Prevention and Treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of Harm Reduction at the same university. He receives

consultancy fees from Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, and Sermo Inc. He receives textbook royalties from Elsevier. He is also involved in a patent application for ECLAT Srl. He is an unpaid scientific advisor for Lega Italiana Anti Fumo (LIAF) and the International Network of Nicotine Consumers Organizations (INNCO); and is Chair of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). D. D. Sin has received speakers’ honoraria from GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca. N. C. Thomson declares that he has no relevant conflicts of interest.

Received for publication March 10, 2022; revised April 27, 2022; accepted for publication April 29, 2022.

Available online ■■

Corresponding author: Neil C. Thomson, MD, Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow G12 0YN, United Kingdom.
E-mail: neil.thomson@glasgow.ac.uk.

2213-2198

© 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<https://doi.org/10.1016/j.jaip.2022.04.034>

Abbreviations used

<i>ACO</i>	- Asthma-COPD overlap
<i>AHR</i>	- Airway hyperreactivity
<i>COPD</i>	- Chronic obstructive pulmonary disease
<i>CT</i>	- Computed tomography
<i>FeNO</i>	- Fractional concentration of exhaled nitric oxide
<i>FEV₁</i>	- Forced expiratory volume in 1 second
<i>GINA</i>	- Global Initiative for Asthma
<i>GR</i>	- Glucocorticoid receptor
<i>ICS</i>	- Inhaled corticosteroid
<i>LABA</i>	- Long-acting β_2 -agonist
<i>LAMA</i>	- Long-acting muscarinic antagonist
<i>MART</i>	- Maintenance and reliever therapy
<i>T2 inflammation</i>	- Type 2 inflammation
<i>WHO</i>	- World Health Organization

Cigarette smoking and asthma interact to induce a mixed “asthma-smoking phenotype,” which has important implications for diagnosis, pathogenic mechanisms, and management.

The lack of progress in understanding the impact of smoking on adults with asthma is due in part to their exclusion from investigative studies and large clinical trials because of concerns that these patients may also have chronic obstructive pulmonary disease (COPD). The review aims to summarize the adverse clinical outcomes associated with cigarette smoking in asthma and to answer the following key questions: (1) What are the main issues that clinicians should consider when making a diagnosis of asthma in adults with chronic respiratory symptoms and a smoking history? (2) Why do patients with asthma and smoking history have worse clinical outcomes? (3) What is the best approach to managing patients with asthma and a smoking history? The article provides an update on earlier reviews of smoking and asthma.^{9,10}

ADVERSE CLINICAL OUTCOMES

Epidemiological data have demonstrated that current and former cigarette smoking¹¹⁻¹³ and cumulative pack-years of smoking¹⁴ are risk factors for the development of asthma in adults. Numerous observational studies have shown that current smoking is frequently associated with worse clinical outcomes in asthma¹⁵ (Figure 1) including suboptimal asthma control,^{7,16} lower asthma or generic health-related quality of life domain scores,^{17,18} more exacerbations,¹⁹⁻²¹ greater asthma-related health care utilization,²² and a higher proportion of individuals with chronic bronchitis.^{23,24} Likewise, greater cumulative exposure to cigarette smoke is associated with worse asthma control²⁵ and predicted asthma-related hospital admissions in adult-onset asthma.²⁶

In asthma, current smoking status and cumulative exposure to cigarette smoke^{27,28} are associated with the development of persistent airflow obstruction over time, especially after 50 years of age, leading to asthma-COPD overlap (ACO) in some cases.^{29,30} Several longitudinal population-based studies³¹⁻³⁴ reported an accelerated decline in lung function from early adulthood among current smokers with asthma compared with never smokers with asthma, which was associated with a higher pack-year history in middle-aged adults with asthma.³⁵ For example, data from the Busselton Health Study showed that compared with never smokers with asthma, heavy smoking accelerated the decline by 14 mL/year in males and 7 mL/year in

females³⁴ (Figure 2). In the longitudinal population-based European Community Respiratory Health Survey, early- and late-onset asthma (defined as onset after 10 years of age) were both associated with a 10- to over 20-fold increase in the risk of adult airflow obstruction. The development of persistent airflow obstruction was independent of smoking among early-onset asthma, whereas cigarette smoking increased the risk in the late-onset asthma subgroup (25-fold increase) compared with never smoking (11-fold increase), particularly among nonatopic subjects (30-fold increase).³² Suboptimal lung growth from early-life events may contribute to persistent airflow obstruction in adulthood among some current smokers with asthma.³⁶

Several surveys of current smokers with asthma report a higher prevalence of comorbidities such as anxiety and depression,²¹ osteoporosis,³⁷ cardiovascular diseases,⁷ lung cancer,^{7,38} and pneumonia^{7,39} compared with never smokers with asthma. The cause of comorbidities in current smokers with asthma is likely to be multifactorial due to cigarette smoking, asthma, and/or oral corticosteroid burden. Current smoking is an important risk factor for increased all-cause mortality in asthma,⁴⁰ particularly in global regions with low socio-demographics.⁴¹

DIAGNOSIS AND DESCRIPTION

Based on symptoms of wheeze, cough, chest tightness, and/or dyspnea and objective evidence of variable expiratory airflow limitation,⁴² the diagnosis of asthma in younger adults with a smoking history is often straightforward. In some cases, measuring airway hyperreactivity (AHR) to methacholine confirms the diagnosis, although even in the absence of asthma, cigarette smoking increases the occurrence of AHR by over 3-fold in heavy daily smokers (≥ 25 cigarettes/day).⁴³ Some have proposed the addition of fractional concentration of exhaled nitric oxide (FeNO) measurements for individuals whose diagnosis of asthma remains uncertain,⁴⁴ but values are decreased in current smokers,⁴⁵ limiting its diagnostic value. Distinguishing asthma from symptomatic smokers without spirometry COPD (pre-COPD)^{15,46,47} or with COPD is more problematic in older individuals with a long-standing smoking history. Data from several studies have demonstrated the poor sensitivity of bronchodilator reversibility,⁴⁸ AHR,⁴³ diffusing capacity of lung to carbon monoxide, computed tomography (CT) imaging of the chest, or biomarkers to differentiate asthma- from smoking-related chronic airway disease.⁴⁹ Furthermore, several smoking-associated phenotypes have emerged from cluster analysis studies of asthma populations that included adults with asthma and a smoking history.⁵⁰⁻⁶¹ The main variables identified were smoking status, age of onset of asthma, severity of asthma, airflow obstruction, and type 2 inflammation (T2) status (Figure 3). Although these clusters provide insights into the heterogeneity of asthma-smoking phenotypes, their clinical relevance is uncertain. Given the substantial risk of diagnostic misclassification of chronic airway disease in symptomatic current and former smokers,^{15,62} particularly in older age groups, we recommend an approach that involves an assessment of the probability that clinical features are suggestive of a diagnosis of asthma- or smoking-related ACO as outlined in the Global Initiative for Asthma (GINA) report⁴² and that describes individual clinical, physiological, pathological, biomarker variables and treatable traits.^{63,64}




FIGURE 1. Summary of adverse clinical outcomes in current smokers with asthma compared with never smokers with asthma. Created with BioRender.com.




FIGURE 2. The average annual rate of decline in FEV_1 of a typical 49-year-old heavy smoker and never smoker with and without asthma according to sex. Reference indicates lifetime never smokers without asthma. FEV_1 , Forced expiratory volume in 1 second. Created from James et al.³⁴

MECHANISMS OF DISEASE

Multiple risk factors contribute to the adverse health outcomes experienced by smokers with asthma. Risk factors include current or former smoking status, cumulative exposure to cigarette smoke, asthma phenotypes such as nonatopic late-onset asthma,³² and coexistent social factors such as lower socioeconomic status, environmental exposures such as passive smoke⁶⁵ or air pollution,⁶⁶ and behavioral factors. Furthermore, early-life events such as maternal smoking, prematurity, early

respiratory infection, and previous severe childhood-onset asthma⁶⁷ can contribute to suboptimal lung growth and submaximal lung function that impacts lung function in adulthood. The exposure to different risk factors is likely to induce heterogeneous phenotypes and endotypes.

Cellular and structural changes

Cigarette smoking can alter airway eosinophil and neutrophil numbers in asthma. Although airway eosinophils were reduced in




FIGURE 3. Asthma smoking phenotypes identified from cluster analysis studies that included current and former smokers with asthma. COPD, Chronic obstructive pulmonary disease. *Summary data from cluster analysis studies that included current and former smokers with asthma.⁵⁰⁻⁶¹ Created with BioRender.com.

some studies,^{21,68-70} more often eosinophil numbers were unaltered by smoking status.⁷¹⁻⁷⁵ A recent study of predominately former smokers with severe asthma found that a ≥ 10 -pack-year history was associated with higher proportion of patients with eosinophilic airway inflammation, autoimmunity toward eosinophils, and reduced sputum eosinophil sensitivity to systemic corticosteroids, suggesting a phenotype of severe refractory eosinophilic asthma among former smokers with a history of a higher cumulative exposure to cigarette smoke.⁷⁶ Many studies have shown that current smoking was associated with neutrophilic airway inflammation,^{68,71,74} whereas other data have shown that neutrophil numbers did not differ from never smokers.^{21,69,70,77} A cross-sectional study of over 800 adults with mild-to-severe asthma found similar proportions with eosinophilic, neutrophilic, and paucigranulocytic inflammation among current smokers (37%, 15%, and 45%, respectively) compared with never smokers (43%, 16%, and 37%, respectively).⁷² Differences in risk factors may explain the variability in eosinophil and/or neutrophil numbers between studies. Overall, data from these studies have shown that over one-third of current smokers with mild-to-severe asthma have airway eosinophilia and over one-half have neutrophilic or paucigranulocytic airway inflammation. In addition, exposure to cigarette smoke in adults with asthma is associated with the recruitment, activation, and/or altered function of macrophages,⁷⁸ dendritic cells,⁷⁹ mast cells,⁷⁰ natural killer cells,⁸⁰ and T and B cells^{75,79} compared with never smokers, although data are limited, and some findings are conflicting.

Structural changes to the airway epithelium associated with cigarette smoking in asthma include increased goblet cell numbers,^{70,77} epithelial cell hyperplasia,⁷⁰ and squamous metaplasia. Pathological features of epithelial remodeling may underlie respiratory symptoms because increased goblet cell numbers correlated with a self-reported history of sputum production and greater epithelial thickness correlated with self-reported breathlessness.⁷⁰ The percentage of mucus positive epithelium, epithelial thickness, and proliferating epithelial cells

in former smokers was similar to never smokers with asthma,⁷⁰ suggesting reversal of epithelial cell remodeling after smoking cessation. Several studies have found that basement membrane thickness,^{70,75,77} histological airway smooth muscle area thickness,^{75,77} and wall thickness on CT⁸¹ were not associated with smoking status in adults with mild-to-severe asthma. In contrast, data from other CT imaging studies found increased airway wall thickness in current smokers with asthma⁷⁴ and among ACO patients with a cumulative smoking history of ≥ 20 pack-years compared with those with < 5 pack-years.⁸² CT emphysema is typically absent from adults with asthma and a smoking history,^{81,82} although visual analysis showed a greater prevalence of emphysema in smoking-related ACO (≥ 20 pack-years) compared with those with ACO (< 5 pack-years).⁸² Collectively, these findings suggest remodeling of the epithelium and possibly other lung structures among current smokers with asthma.

Pathogenesis

Pathogenic mechanisms underlying airway inflammation and tissue remodeling in smokers with asthma are poorly understood but are thought to involve interactions between smoking- and asthma-related airway inflammation (Figure 4). Exposure to cigarette smoke induces oxidative stress⁸³ and the release of proinflammatory mediators by activated neutrophils, macrophages, and CD8⁺ cytotoxic T cells.⁸⁴ Exposure to allergens in sensitized individuals or other stimuli induces proinflammatory mediator release from activated eosinophils, T helper 2 cells, type 2 innate lymphoid cells, and mast cells. Collectively, these inflammatory pathways cause T2-low and/or T2-high airway inflammation and tissue damage to the epithelium and other structures. Innate immune responses mediated by epithelial cells, alveolar macrophages, dendritic cells, and natural killer cells can be suppressed by exposure to cigarette smoke and thus impair host responses against infection.⁸⁵ Corticosteroid insensitivity occurs because of refractory eosinophilic, neutrophilic, or paucigranulocytic airway inflammation, in addition to other causes




FIGURE 4. Schematic diagram illustrating potential inflammatory pathways underlying airway immunopathology of asthma in adults with a smoking history. Exposure to cigarette smoke, which contains high concentrations of reactive oxygen species (ROS), activates airway epithelial cells to synthesize proinflammatory mediators such as IL-8 and IL-1 β , which recruit and/or activate neutrophils, macrophages, and CD8⁺ cytotoxic T cells (Tc1). Activated neutrophils secrete ROS, proteases, and inflammatory mediators, such as matrix metalloproteinase (MMPs), and can form neutrophil extracellular traps (NETs). Excessive NET formation (NETosis) induces T helper (Th)17 responses that contribute to neutrophilic inflammation. Activated macrophages secrete proteases, MMPs, and chemokines that attract neutrophils, Th17, Th1 cells, and Tc1 cells. Th17 cells are chemotactic to neutrophils, Tc1 cells secrete serine protease granzyme B, and Th1 cells release IFN γ . Current cigarette smoking in asthma is likely to induce predominately non-T2 inflammation, although T2-high eosinophilic inflammation may coexist due to allergen-induced pathways, NETosis causing DNA-induced T2 responses, and cigarette-smoke–induced release of alarmins such as IL-33, thymic stromal lymphopoietin (TSLP), and IL-25. Exposure to allergens in sensitized individuals and the release of alarmins from injured epithelial cells activate Th2 cells and type 2 innate lymphoid cells (ILC2), respectively, to release T2 cytokines IL-4, IL-5, and IL-13. Dendritic cells process antigens and when activated by alarmins can initiate T2 immunity. IL-4 causes IgE production from B cells and IL-5 recruits and activates eosinophils. Smoking- and asthma-related inflammation cause T2-high and/or T2-low inflammation, tissue remodeling, corticosteroid insensitivity, and impaired host responses, which together contribute to adverse clinical outcomes in current and former smokers with asthma. *NK*, natural killer; *PGD*₂, prostaglandin D₂; *T2*, type 2 inflammation. Created with [BioRender.com](https://www.biorender.com).

such as nonadherence. Possible molecular mechanisms of corticosteroid insensitivity include altered glucocorticoid receptor (GR) subtypes, such as increased inactive GR β and decreased active GR α expression,⁸⁶ and increased proinflammatory transcription factors activity, such as nuclear factor- κ B, or decreased histone deacetylase activity 2 activity.⁸⁷ In addition to airway

inflammation, low-grade systemic inflammation is found in current and former smokers with asthma,⁷ which in one study was associated with comorbidities, a higher pack-year history, and lower lung function.⁸⁸ Whether low-grade systemic inflammation is a causative factor for adverse clinical outcomes in smokers with asthma is not known.




FIGURE 5. Algorithm for the management of current and former smokers with clinical features suggestive of asthma. *Some patients may have clinical features suggestive of smoking-related ACO. There is a risk of diagnostic misclassification of chronic airway disease such as COPD in symptomatic current and former smokers, particularly in older age groups. Key components of management: ① *Smoking cessation or relapse prevention advice*: smoking cessation advice is a priority component of management among current smokers; relapse prevention advice is an option for recent quitters.⁹⁰ ② *Pharmacological management*: based on Global Initiative for Asthma recommendations, although data are limited on the effectiveness of therapies for current smokers with asthma and there is evidence of corticosteroid insensitivity to ICS treatment. ③ *Assess T2 status*: Among current or former smokers with poorly controlled asthma despite moderate-dose ICS-LABA who have T2-high eosinophilic inflammation (raised blood eosinophil count), consider high-dose ICS-LABA and/or biologics (or low-dose oral corticosteroids). Therapeutic options for patients with persistently poorly controlled asthma associated with T2-low inflammation or associated with treated T2-high inflammation include add-on LAMA for patients with chronic airflow obstruction, a trial of add-on azithromycin, particularly in former smokers, and bronchial thermoplasty. ④ *Target risk factors and behavioral treatable traits*: such as nonadherence, poor inhaler technique, and infection risk. ⑤ *Target extrapulmonary comorbidities*: disease-specific treatment. ICS, inhaled corticosteroid; LABA, long-acting β -agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β -agonist; T2 inflammation, type 2 inflammation.

MANAGEMENT

The management strategy for current smokers with asthma starts with smoking cessation. GINA provides recommendations for drug treatment,⁴² although evidence for the effectiveness of therapies in current smokers with asthma and those with heavier smoking history is uncertain because clinical trial data were generated among never smokers or former smokers with a very low pack-year history, typically 5 pack-years or less. Recently, the identification and targeting of treatable traits have been proposed as a personalized approach to the management of chronic airway diseases,⁶⁴ although data are limited on its effectiveness for the management of current smokers with asthma.⁸⁹ In addition to smoking cessation, management involves the identification and targeting of high-yield treatable risk factors and behavioral traits, such as infection and poor adherence with asthma therapies; pulmonary traits, such as exacerbations, airflow obstruction, and T2 eosinophilic inflammation; and extrapulmonary traits, such as comorbidities (Figure 5). Published evidence for the effectiveness of specific components of a management plan for adults with asthma and a smoking history is reviewed below.

Smoking cessation

All smokers with asthma should be advised to quit. This advice should be personalized by listing the improvements in asthma outcomes soon after quitting. In several studies in asthma, quitting smoking is associated with improvements in symptoms,⁹¹⁻⁹³ asthma-related quality of life,⁹¹ lung function,⁹³ and AHR.^{91,92} Furthermore, former smokers with asthma often have better symptom control than current smokers.^{21,94} A COPD risk-prediction model estimated that a 43-year-old female unskilled worker with asthma who smoked 20 cigarettes/day for 30 years had an estimated 42% risk of COPD in the next 10 years, but only 4.5% if she stopped smoking at age 43.⁹⁵ Cigarette smokers with asthma and COPD are no more likely to receive smoking cessation counseling and pharmacotherapy from physicians compared with the general smoking population.⁹⁶ Cigarette smoking quit rates are improved with behavioral counseling in combination with pharmacotherapies, such as nicotine replacement products, varenicline, and bupropion.⁹⁷ A tailored approach to the smoking cessation of the smokers with asthma has been described previously.^{98,99} Although the

TABLE I. Selected studies of the efficacy of inhaled corticosteroid treatment in current smokers with asthma compared with never smokers with asthma

Reference	Study design	No. of participants	Mean age (y)	Mean baseline FEV ₁ % predicted	Mean pack-year history	ICS dose and duration	Main outcome
ICS treatment for ≤3 mo							
Chalmers, 2002 ¹⁰⁵	Randomized, placebo-controlled, cross-over	CS/NS 17/21	CS/NS 35/35	CS/NS 87/88	CS 17	FP 1000 µg daily for 3 wk	Improvement in morning PEF greater in NS than in CS (27 L/min vs -5 L/min) ($P = .006$) Within-group improvement in FEV ₁ (0.17 L), geometric mean PC ₂₀ (2.6 doubling dose), and a decrease in the proportion of sputum eosinophils (-1.75%) after FP compared with placebo among NS, with no improvement in these outcomes in CS
Tomlinson, 2005 ¹⁰⁶	Randomized, parallel-group	CS/NS 40/55*	CS/NS 46/43	CS/NS 86/85	CS/NS 25/3	BDP 400 µg and 2000 µg daily for 3 mo	Among those receiving 400 µg daily, the improvement in mean (95% CI) morning PEF (L/min) in CS was less than NS (-25, -45 to -4) ($P = .02$). Among those receiving 2000 µg BDP daily, the difference was reduced between CS and NS
Lazarus, 2007 ¹⁰⁷	Randomized, cross-over	CS/NS 39/44†	CS/NS 29/29	CS/NS 78/80	CS/NS 7/0	BDP 400 µg daily for 8 wk	Improvement in FEV ₁ in NS (170 mL, $P = .0003$) and no improvement in CS Improvement in PEF and reduction in sputum eosinophils similar between NS and CS
Clearie, 2012 ¹⁰⁸	Randomized, controlled, cross-over	CS/NS 15/16	CS/NS 38/39	CS/NS 88/83	CS 14	FP 500 µg daily for 2 wk	Improvement in methacholine PC ₂₀ was greater in NS than in CS: 2.5 doubling doses ($P < .01$) Improvement in FEV ₁ was greater in NS than in CS: 7.9% ($P = .02$) Within-group improvement in ACQ in NS, but not in CS
Telenga, 2013 ⁶⁹	Randomized, controlled	CS/FS/NS 30/29/55	CS/FS/NS 27/38/25	CS/FS/NS 78/79/82	CS/FS 7/7	FP 500 µg and 2000 µg daily for 2 wk	Improvement in FEV ₁ was lower in CS compared with NS ($P = .01$) and in FS compared with NS ($P = .07$) Improvement in FEV ₁ in NS of 8% ($P < .001$) but no improvement in FEV ₁ in CS (2.4%) ($P = .17$) or FS (4%) ($P = .07$) A higher pack-year history was associated with less improvement in FEV ₁
ICS treatment for ≤1 y							
Pedersen, 2007 ¹¹⁰	Post hoc analysis of the GOAL randomized controlled, parallel-group trial	CS/FS/NS 142/306/1259	Total group 40	CS/FS/NS 77/76/77	CS/FS <10	FP up to 1000 µg daily alone or combined with inhaled salmeterol for 1 y	A higher proportion of CS receiving inhaled medium- to high-dose FP had severe exacerbations compared with NS (0.35 vs 0.17 per patient per year, respectively) ($P = .012$)

(continued)

TABLE I. (Continued)

Reference	Study design	No. of participants	Mean age (y)	Mean baseline FEV ₁ % predicted	Mean pack-year history	ICS dose and duration	Main outcome
O'Byrne, 2009 ¹¹¹	Post hoc analysis of the START randomized placebo-controlled	CS/NS 263/1183	CS/NS 32/35	CSNS 88/86	Not recorded	BUD 400 µg daily for 3 y	Improvement in pre- and post-BD FEV ₁ was similar in CS and NS
Dijkstra, 2006 ¹¹²	Observational	CS/FS/NS 55/7/60	Total group 28	Total group 85	Total group 0.1	ICS (dose and formulation not specified) for a mean follow-up of 23 y	The decline in FEV ₁ was reduced in male CS with a <5-pack-year history after ICS, but no effect of ICS on the decline in FEV ₁ among women or CS with a >5-pack-year history
Lange, 2006 ¹¹³	Observational	CS/NS 76/158	Total group (range 52 to 58)	Total group 83	Not recorded	ICS (dose and formulation not specified) for 10 y	ICS treatment compared with no ICS treatment associated with a 27 mL per year lower decline in FEV ₁ among smokers
Telenga, 2013 ⁶⁹	Observational (open-label follow-up from randomized controlled)	CS/FS/NS 16/16/32	CS/FS/NS 29/37/25	Not recorded	Not recorded	FP 500 µg and 2000 µg daily for 2 wk, then FP 500 µg daily group continued for 50 wk (1 y in total)	Improvement in FEV ₁ was similar between the NS, CS, and FS groups after 1 y Improvement in FEV ₁ in NS of 10% ($P < .001$), in FS of 5% ($P = .01$), but no improvement in FEV ₁ in CS (3%) ($P = .06$)

ACQ, Asthma Control Questionnaire; BD, bronchodilator; BDP, beclometasone dipropionate; BUD, budesonide; CI, confidence interval; CS, current smoker; FEV₁, forced expiratory volume in 1 second; FP, fluticasone propionate; FS, former smoker; GOAL, Gaining Optimal Asthma Control; ICS, inhaled corticosteroid; NS, never smoker; PC₂₀, provocative concentration that produced a 20% fall in FEV₁; PD₁₅, provocative dose that produced a 15% fall in FEV₁; PEF, peak expiratory flow; START, inhaled Steroid Treatment As Regular Therapy.

*Study included a small number of nonsmokers defined as follows: stopped smoking over 5 years ago and had smoked ≤5 pack-years.

†Study included a small number of nonsmokers defined as follows: stopped smoking at least 1 year ago and had smoked <2 pack-years.

preferred goal is abstinence, this is not always achievable and substitution of conventional cigarettes with alternatives that do not require combustion to deliver nicotine such as E-cigarettes may be an alternative for those smokers with asthma who do not wish to stop smoking.^{100,101}

Targeting nonadherence, poor inhaler technique, and infection risk

Cigarette smoking has been associated with poorer adherence to drug therapies for asthma in some¹⁰² but not all studies.¹⁰³ An international cross-sectional study of over 4000 adults with asthma identified current smoking as a risk factor for ≥ 1 inhaler technique errors and worsening asthma outcomes among those who used a metered-dose inhaler but not among those who used a dry powder inhaler device.¹⁰⁴ Infection risk reduction for current smokers with asthma including smoking-related ACO involves annual influenza vaccination,⁴² COVID-19 vaccination, and pneumococcal vaccination for patients >65 years.⁴⁹

Drug treatments and other therapies

Published studies on the influence of current smoking status on GINA recommendations for the treatment of symptoms, exacerbations, and airflow obstruction in adolescents and adults with asthma are summarized in the following section.

Maintenance low- to high-dose inhaled corticosteroids (ICS). Data from several small randomized controlled trials have shown reduced improvement in lung function after low- to medium-dose ICS administered from <1 month to 6 months among current smokers with mild-to-moderate asthma compared with never smokers (Table 1).^{69,105-108} In one study, current smokers with asthma who were insensitive to low-dose ICS improved lung function after high-dose ICS therapy for 12 weeks,¹⁰⁶ suggesting that smokers with mild-to-moderate asthma may require a higher dose ICS treatment to overcome corticosteroid insensitivity and improve airflow obstruction. The beneficial effect of low-dose ICS on allergen-induced early asthmatic responses is attenuated in current smokers with asthma.¹⁰⁹ A *post hoc* analysis of the Gaining Optimal Asthma Control trial showed that 1-year treatment with medium- to high-dose ICS was less effective in preventing severe exacerbations in current compared with never smokers with asthma.¹¹⁰ Data from a *post hoc* analysis of the inhaled Steroid Treatment as Regular Therapy trial in recent-onset mild asthma¹¹¹ and observational studies^{112,113} have shown that long-term ICS treatment (≥ 1 year) reduced the decline in lung function among current smokers with asthma, although in one observational study, a beneficial effect of ICS was restricted to men and smokers with a <5 -pack-year history.¹¹² Two systematic reviews have shown that current smoking was associated with a reduced improvement in forced expiratory volume in 1 second (FEV₁) after low- and high-dose ICS treatment compared with non-smokers.^{114,115} Exploratory analysis of the UK General Practice Database has found a lower rate of severe exacerbations and improvement in asthma control for current and former smokers with asthma after 1 year's treatment with extra-fine-particle ICS compared with standard-particle ICS,¹¹⁶ although other studies have not found better outcomes with extra-fine-particle ICS in current smokers with asthma.¹¹⁷ Data from one study in asthma have shown that a higher pack-year history was associated with reduced improvement in FEV₁ after 2-week and 1-year

treatment with ICS.⁶⁹ Collectively, these findings suggest that the improvement in lung function after short-term low- to medium-dose ICS is impaired among current smokers with asthma compared with never smokers. In current smokers with asthma, long-term treatment with ICS may reduce the decline in lung function but it is less effective in preventing exacerbations compared with never smokers with asthma. Preliminary data from clinical trials in current and former smokers with asthma^{110,111} or COPD¹¹⁸⁻¹²⁰ suggest that the beneficial effects of ICS on exacerbations and lung function are greater in former smokers than in current smokers.

As-needed low-dose ICS-formoterol reliever. The GINA recommendation for the use of as-required ICS-formoterol in symptomatic mild or moderate asthma is based on evidence from large clinical trials generalizable to current or former smokers with a low cumulative smoking history.¹²¹⁻¹²⁴ Currently, there are no clinical trials that have assessed the as-needed low-dose ICS-formoterol reliever strategy in smokers with medium to high tobacco use.¹²⁵

Maintenance low- to high-dose ICS-long-acting β_2 -agonist (LABA). Maintenance medium- to high-dose standard-particle ICS-LABA combination in current and former smokers with asthma produced greater improvement in asthma control and reduction in exacerbations than high-dose ICS.^{108,110,117} Data on the effectiveness of low-dose ICS-LABA maintenance treatment, including extra-fine particle ICS-LABA,¹²⁶ are limited to findings from a small number of observational studies.

ICS-LABA maintenance and reliever therapy (MART) regimen. A study of medium-dose maintenance budesonide/formoterol (200/6 μg) 2 puffs twice daily showed that the reduction in severe exacerbations with low-dose budesonide/formoterol (200/6 μg) 1 puff (MART regimen) compared with short-acting β_2 -agonist for symptom relief was unrelated to smoking status among 303 adults with asthma of whom half were current or former smokers with <10 pack-year smoking history.¹²⁷ A 6-month open-label study in light smokers with asthma found that the reduction in symptoms and severe exacerbations was greater with the MART regimen using medium-dose budesonide/formoterol (200/6 μg) 2 puffs twice daily compared with 1 inhalation twice daily suggesting that a higher maintenance dose of budesonide/formoterol may be required in smokers with asthma.¹²⁸ Collectively, these findings suggest that the MART regimen is effective in current smokers with asthma who have a low cumulative smoking history.

Add-on long-acting muscarinic antagonist (LAMA). A *post hoc* analysis of phase 3 trials of once-daily tiotropium add-on therapy in symptomatic patients with asthma despite treatment with medium- to high-dose ICS with or without LABA reported a reduced time to first severe exacerbation in former smokers with persistent airflow obstruction.¹²⁹ A 12-week randomized placebo-controlled study in 472 current and former heavy cigarette smokers (34 pack-year history) with ACO reported improvements in FEV₁ and a decrease in rescue medication use with add-on tiotropium.¹³⁰ A randomized cross-over trial in 16 current smokers with asthma found that the addition of tiotropium to medium-dose ICS-LABA improved through small airway flow rates, but had no

added effect on symptoms or reliever use.¹³¹ Collectively, these findings suggest benefits from the addition of tiotropium to symptomatic ever smokers with asthma associated with persistent airflow obstruction despite treatment with medium- to high-dose ICS-LABA.

Biologics. *Post hoc* analysis of the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab study showed that omalizumab for 48 weeks improved symptom control, but not lung function, among 50 current and former smokers with ACO compared with 663 adults without ACO, of whom two-thirds were never smokers.¹³² Data from a global observational cohort study of 368 real-world patients newly prescribed mepolizumab for severe asthma, of whom 39% were current smokers or former smokers demonstrated reductions in exacerbations and maintenance oral corticosteroid use similar to those reported in clinical trials of mepolizumab.¹³³ A *post hoc* analysis of a phase 2b trial of the anti-interleukin (IL)-4 receptor α monoclonal antibody dupilumab in patients with severe asthma reported improvements in FEV₁ and reduced severe exacerbations in a subgroup of patients with a smoking history and ACO.¹³⁴ Collectively, these data and other observational studies¹¹⁷ provide low-certainty evidence of clinical benefits from treatment with anti-immunoglobulin E (IgE) omalizumab, anti-IL5 mepolizumab, and anti-IL4 receptor α dupilumab in patients with smoking-related ACO.

Add-on azithromycin. Add-on azithromycin treatment for 12 weeks did not affect clinical outcomes and inflammatory biomarkers among current smokers with mild-to-moderate asthma.¹³⁵ The Asthma and Macrolides: the Azithromycin Efficacy and Safety trial, which recruited 420 never and former smokers (38% of participants; <10 pack-year history) with persistent uncontrolled asthma, showed that the addition of azithromycin for 48 weeks reduced severe and moderate exacerbations and improved asthma-specific quality of life compared with placebo.¹³⁶ In COPD, daily azithromycin decreased acute exacerbations in former smokers, but not in current smokers.¹³⁷ Collectively, these findings suggest that the addition of azithromycin is not effective in current smokers with mild-to-moderate asthma, whereas it may reduce exacerbations in former smokers with asthma who have a low cumulative smoking history.

Low-dose maintenance oral corticosteroid. Several clinical trials showed that the improvement in lung function after short-term high-dose oral corticosteroid treatment was impaired in current smokers with asthma compared with never smokers.^{138,139} The influence of smoking status on low-dose maintenance oral corticosteroid treatment or the efficacy of high-dose oral corticosteroid treatment of exacerbations is not known.

Other therapies. The number of participants with a smoking history included in real-world patient observational studies of bronchial thermoplasty is too small to establish the efficacy or safety of the procedure in current or former smokers with severe asthma.¹⁴⁰ A small number of clinical studies have reported the benefits of the leukotriene receptor antagonist montelukast as a first-line controller therapy in current smokers with asthma.^{107,141} In a controlled clinical trial among 1019 current smokers with asthma, a better clinical response to montelukast

was found in those with a higher cumulative exposure to tobacco smoke (>11 pack-years), whereas a better response to medium-dose ICS was shown in those with lower cumulative exposure to tobacco smoke (\leq 11 pack-years).¹⁴²

Drugs used to treat symptoms of chronic bronchitis, such as thiol compounds¹⁴³ and the phosphodiesterase 4 inhibitor roflumilast, which is an add-on option to reduce exacerbations in current and former smokers with severe COPD and chronic bronchitis,⁴⁹ have not been studied in smokers with asthma and chronic bronchitis. Preliminary studies with statins^{144,145} or low-dose theophylline¹⁴⁶ have shown clinical benefits in current smokers with mild-to-moderate asthma, but larger trials are required.

T2 eosinophilic inflammation status

Current cigarette smoking alters biomarkers of T2 inflammation in asthma, for example, by reducing FeNO⁴⁵ and serum periostin concentrations.¹⁴⁷ Blood eosinophil numbers in current smokers with asthma can be increased,¹⁴⁸ reduced,⁶⁹ or similar^{7,21,149} to never smokers with asthma. Among current smokers (\geq 10-pack-year smoking history) with mild-to-moderate asthma, a single blood eosinophil count (>2%) was shown to be a good predictor of airway eosinophilia.¹⁵⁰ Blood eosinophils are used to identify individuals with T2-high airway inflammation who are potentially suitable for ICS or biologic treatment among adults with asthma (data mainly from non-smokers) and ICS use in smoking-related COPD. Based on these findings, it is likely that blood eosinophils can also be used to predict ICS responsiveness among adults with asthma and a smoking history, although published clinical data are limited. Current smoking is associated with elevated total IgE antibody levels in the general population,¹⁵¹ whereas most studies in asthma have found that total IgE levels are not influenced by smoking status.^{7,21} Smoking is associated with a reduced sensitization to common aeroallergens,¹⁵² except for increased sensitization to house dust mites in some studies.^{21,152}

T2-high eosinophilic inflammation. Over one-third of current smokers with asthma have biomarker evidence of T2-high inflammation.^{147,153,154} In a large UK primary care asthma cohort, of whom over 50% were current and former smokers, a multidimensional eosinophil algorithm classified an eosinophilic phenotype in the majority.¹⁵⁵ Current and former smokers with poorly controlled asthma despite moderate-dose ICS-LABA who have persistently raised blood eosinophils should be considered for high-dose ICS-LABA and/or biologics. The optimum blood eosinophil count cutoff value for high-dose ICS or biologic treatment is uncertain in smokers with asthma. In smoking-related COPD, the addition of ICS to LABA or LABA and LAMA reduced moderate and severe exacerbations^{118,119} at all blood eosinophil counts among former smokers, but among current smokers, clinical benefits were lacking at lower eosinophil counts (<200 cells/ μ L), whereas exacerbations were reduced at higher eosinophil counts (>200 cells/ μ L).^{118,119} In smoking-related ACO, observational data suggested that a blood eosinophil count of >300 cells/ μ L predicted a decrease in exacerbations with ICS.¹⁵⁶ Possible blood eosinophil values predicting ICS responsiveness in current smokers with asthma are >300 cells/ μ L, good ICS response; >100 to 300 cells/ μ L, uncertain ICS response; and \leq 100 cells/ μ L, low probability of ICS response. Collectively, these findings

suggest that former smoking status and elevated blood eosinophil count may predict ICS responsiveness in adults with asthma and a smoking history, although further studies are required to assess the interrelationships between smoking status, blood eosinophil count, ICS responsiveness, exacerbations, and severity of asthma.

T2-low neutrophilic and/or paucigranulocytic inflammation. Around 50% of adults with asthma and a smoking history have neutrophilic or paucigranulocytic airway inflammation. T2-low inflammation is associated with a high cumulative exposure to tobacco smoke.^{52,157} Specific drug therapies are not currently available to target T2-low inflammation.

Overview of management

As an aid for clinicians, an algorithm summarizes the key components of the management of current and former smokers with clinical features suggestive of asthma- and/or smoking-related ACO (Figure 5) and emphasizes the central place of smoking cessation for current smokers. Despite limited data on the effectiveness of therapies for current smokers with asthma, pharmacological management is based on GINA recommendations.⁴² Overall, published data suggest that smoking status (current vs former smokers),^{110,111,138} cumulative smoking exposure,⁶⁹ and biomarker evidence of T2 high eosinophilic inflammation influence the therapeutic response to pharmacological and biological interventions. Blood eosinophil count should be used to assess T2 status in current and former smokers with poorly controlled asthma despite maintenance medium-dose ICS-LABA combination treatment before considering high-dose ICS-LABA and/or biologics (or low-dose oral corticosteroids) for those with persistently raised blood eosinophils. Therapeutic options for patients with persistently poorly controlled asthma despite moderate-dose ICS-LABA and T2-low inflammation or with treated T2-high inflammation include add-on LAMA for patients with chronic airflow obstruction, a trial of add-on azithromycin, particularly in former smokers, and bronchial thermoplasty. Management also includes targeting risk factors, and behavioral and extrapulmonary comorbidity treatable traits. In the future, controlled trials and pragmatic trials in real-world populations should include cigarette smokers with asthma to provide evidence on the effectiveness of drug and biologic treatments in this subgroup of chronic airway disease.

CONCLUSIONS

Globally, adults with asthma frequently give a history of current or previous cigarette smoking. Current smoking is a risk factor for the development of asthma and worse clinical outcomes including suboptimal asthma control, increased exacerbations, accelerated decline in lung function, persistent airflow obstruction, more comorbidities, and higher all-cause mortality. Although diagnosing asthma in symptomatic younger adults with a smoking history can be straightforward, distinguishing asthma from smoking-related chronic airway diseases such as COPD can be difficult, particularly in older individuals with a long-standing smoking history. Given the substantial risk of diagnostic misclassification in symptomatic smokers, we recommend an approach that involves an assessment of the probability that clinical features are suggestive of a diagnosis of asthma- or

smoking-related ACO as outlined in the GINA report and that describes clinical, physiological, pathological, and/or biomarker variables and treatable traits. Exposure to cigarette smoke and other risk factors cause pathogenic mechanisms involving smoking- and asthma-related airway inflammation, tissue remodeling, corticosteroid insensitivity, and low-grade systemic inflammation. The key components of the management strategy for current smokers with asthma include smoking cessation advice, targeting risk factors, and behavioral and extrapulmonary comorbidity treatable traits. Despite limited data on the effectiveness of therapies and evidence of reduced sensitivity to ICS treatment, pharmacological management is based on GINA recommendations. T2-high eosinophilic inflammation should be confirmed before a step-up to high-dose ICS or the use of biologics. Controlled trials and pragmatic trials are required in real-world populations that include cigarette smokers with asthma to provide data on the effectiveness of drug and biologic treatments.

REFERENCES

1. WHO global report on trends in prevalence of tobacco use 2000-2025. 4th ed. Geneva: World Health Organization. Accessed January 24, 2022. <https://www.who.int/publications/i/item/9789240039322>
2. To T, Stanojevic S, Moores G, Gershon A, Bateman E, Cruz A, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. *BMC Public Health* 2012;12:204.
3. Silverman RA, Hasegawa K, Egan DJ, Stiffler KA, Sullivan AF, Camargo CA Jr. Multicenter study of cigarette smoking among adults with asthma exacerbations in the emergency department, 2011–2012. *Respir Med* 2017;125:89-91.
4. Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR). *Chest* 2020;157:790-804.
5. Ryan D, Heatley H, Heaney LG, Jackson DJ, Pfeffer PE, Busby J, et al. Potential severe asthma hidden in UK primary care. *J Allergy Clin Immunol Pract* 2021;9:1612-23. e9.
6. Nwaru BI, Ekerljung L, Rådinger M, Bjerg A, Mincheva R, Malmhäll C, et al. Cohort profile: the West Sweden Asthma Study (WSAS): a multidisciplinary population-based longitudinal study of asthma, allergy and respiratory conditions in adults. *BMJ Open* 2019;9:e027808.
7. Çolak Y, Afzal S, Nordestgaard BG, Lange P. Characteristics and prognosis of never-smokers and smokers with asthma in the Copenhagen General Population Study. A prospective cohort study. *Am J Respir Crit Care Med* 2015;192:172-81.
8. Mattiuzzi C, Lippi G. Estimation of worldwide burden of smoking-related asthma. *Int Arch Allergy Immunol* 2020;181:292-5.
9. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. *Eur Respir J* 2004;24:822-33.
10. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. *Eur Respir J* 2013;41:716-26.
11. Coogan PF, Castro-Webb N, Yu J, O'Connor GT, Palmer JR, Rosenberg L. Active and passive smoking and the incidence of asthma in the Black Women's Health Study. *Am J Respir Crit Care Med* 2015;191:168-76.
12. Skaaby T, Taylor AE, Jacobsen RK, Paternoster L, Thuesen BH, Ahluwalia TS, et al. Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium. *Sci Rep* 2017;7:2224.
13. Jayes L, Haslam PL, Gratziau CG, Powell P, Britton J, Vardavas C, et al. SmokeHaz: systematic reviews and meta-analyses of the effects of smoking on respiratory health. *Chest* 2016;150:164-79.
14. Polosa R, Knoke JD, Russo C, Piccillo G, Caponnetto P, Sarva M, et al. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. *J Allergy Clin Immunol* 2008;121:1428-34.
15. Thomson NC. Asthma and smoking-induced airway disease without spirometric COPD. *Eur Respir J* 2017;49:1602061.
16. Braido F, Brusselle G, Guastalla D, Ingrassia E, Nicolini G, Price D, et al. Determinants and impact of suboptimal asthma control in Europe: the International Cross-sectional and Longitudinal Assessment on Asthma Control (LIAISON) study. *Respir Res* 2016;17:51.

17. Upton J, Lewis C, Humphreys E, Price D, Walker S. Asthma-specific health related quality of life of people in Great Britain: a national survey. *J Asthma* 2016;53:975-82.
18. Jansson S-A, Axelsson M, Hedman L, Leander M, Stridsman C, Rönmark E. Subjects with well-controlled asthma have similar health-related quality of life as subjects without asthma. *Respir Med* 2016;120:64-9.
19. The health consequences of smoking: 50 years of progress. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
20. Bloom CI, Nissen F, Douglas JJ, Smeeth L, Cullinan P, Quint JK. Exacerbation risk and characterisation of the UK's asthma population from infants to old age. *Thorax* 2018;73:313-20.
21. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. *J Allergy Clin Immunol* 2013; 131:1008-16.
22. Noble M, Burden A, Stirling S, Clark A, Musgrave S, Al Sallakh M, et al. Predicting asthma-related crisis events using routine electronic healthcare data. *Br J Gen Pract* 2021;71:e948-57.
23. Thomson N, Chaudhuri R, Messow CM, Spears M, MacNee W, Connell M, et al. Chronic cough and sputum production are associated with worse clinical outcomes in stable asthma. *Respir Med* 2013;107:1501-8.
24. Suzuki K, Tanaka H, Kaneko S, Nishi M, Teramoto S, Itoh S, et al. Respiratory symptoms and cigarette smoking in 3,197 pulmonologist-based asthmatic patients with a highly prevalent use of inhaled corticosteroid. *J Asthma* 2003;40:243-50.
25. Polosa R, Russo C, Caponnetto P, Bertino G, Sarva M, Antic T, et al. Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. *Respir Res* 2011;12:16.
26. Tommola M, Ilmarinen P, Tuomisto LE, Lehtimäki L, Niemelä O, Nieminen P, et al. Cumulative effect of smoking on disease burden and multimorbidity in adult-onset asthma. *Eur Respir J* 2019;54:1801580.
27. To T, Zhu J, Gray N, Feldman LY, Villeneuve PJ, Licskai C, et al. Asthma and chronic obstructive pulmonary disease overlap in women. Incidence and risk factors. *Ann Am Thorac Soc* 2018;15:1304-10.
28. Morgan BW, Grigsby MR, Siddharthan T, Chowdhury M, Rubinstein A, Gutierrez L, et al. Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. *J Allergy Clin Immunol* 2019;143:1598-606.
29. Leung JM, Sin DD. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. *BMJ* 2017;358:j3772.
30. Thomson NC. The role of smoking in asthma and chronic obstructive pulmonary disease overlap. *Immunol Allergy Clin North Am* 2022.
31. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. *N Engl J Med* 1998;339: 1194-200.
32. Aanerud M, Carsin A-E, Sunyer J, Draatva J, Gislason T, Jarvis D, et al. Interaction between asthma and smoking increases the risk of adult airway obstruction. *Eur Respir J* 2015;45:635-43.
33. Perret JL, Dharmage SC, Matheson MC, Johns DP, Gurrin LC, Burgess JA, et al. The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. *Am J Respir Crit Care Med* 2013; 187:42-8.
34. James AL, Palmer LJ, Kicic E, Maxwell PS, Lagan SE, Ryan GF, et al. Decline in lung function in the Busselton health study: the effects of asthma and cigarette smoking. *Am J Respir Crit Care Med* 2005;171:109-14.
35. Tommola M, Ilmarinen P, Tuomisto LE, Haanpää J, Kankaanranta T, Niemelä O, et al. The effect of smoking on lung function: a clinical study of adult-onset asthma. *Eur Respir J* 2016;48:1298-306.
36. Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. *N Eng J Med* 2015;373:111-22.
37. Chalitsios CV, McKeever TM, Shaw DE. Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study. *Eur Respir J* 2021;57:2001251.
38. Lemmetyinen RE, Karjalainen JV, But A, Renkonen RLO, Pekkanen JR, Toppila-Salmi SK, et al. Higher mortality of adults with asthma: a 15 year follow-up of a population-based cohort. *Allergy* 2018;73:1479-88.
39. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. *Thorax* 2015;70:984-9.
40. Engelkes M, de Ridder M, Svensson E, Berencsi K, Prieto-Alhambra D, Lapi F, et al. Multinational cohort study of mortality in patients with asthma and severe asthma. *Respir Med* 2020;2:105919.
41. Li X, Cao X, Guo M, Xie M, Liu X. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. *BMJ* 2020;368:m234.
42. Global Initiative for Asthma. *Global Strategy for Asthma Management and Prevention* 2021. Accessed January 24, 2022. Available from: www.ginaasthma.org.
43. Jansen DF, Schouten JP, Vonk JM, Rijcken B, Timens W, Kraan J, et al. Smoking and airway hyperresponsiveness especially in the presence of blood eosinophilia increase the risk to develop respiratory symptoms: a 25-year follow-up study in the general adult population. *Am J Respir Crit Care Med* 1999;160:259-64.
44. Cloutier MM, Baptist AP, Blake KV, Brooks EG, Bryant-Stephens T, DiMango E, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol* 2020;146:1217-70.
45. Ahovuo-Saloranta A, Csonka P, Lehtimäki L. Basic characteristics and clinical value of FeNO in smoking asthmatics—a systematic review. *J Breath Res* 2019;13:034003.
46. Thomson NC. Asthma with a smoking history and pre-chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2021;204:109-10.
47. Han MK, Agustí A, Celli BR, Criner GJ, Halpin DMG, Roche N, et al. From GOLD 0 to Pre-COPD. *Am J Respir Crit Care Med* 2021;203:414-23.
48. Janson C, Malinovschi A, Amaral AFS, Accordini S, Bousquet J, Sonia Buist A, et al. Bronchodilator reversibility in asthma and COPD: Findings from three large population studies. *Eur Respir J* 2019;54:1900561.
49. Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease*; 2021. Accessed January 24, 2022. <http://www.goldcopd.org>
50. Fingleton J, Huang K, Weatherall M, Guo Y, Ivanov S, Bruijnzeel P, et al. Phenotypes of symptomatic airways disease in China and New Zealand. *Eur Respir J* 2017;50:1700957.
51. Ilmarinen P, Tuomisto LE, Niemelä O, Tommola M, Haanpää J, Kankaanranta H. Cluster analysis on longitudinal data of patients with adult-onset asthma. *J Allergy Clin Immunol Pract* 2017;5:967-978.e3.
52. Konno S, Taniguchi N, Makita H, Nakamaru Y, Shimizu K, Shijubo N, et al. Distinct phenotypes of smokers with fixed airflow limitation identified by cluster analysis of severe asthma. *Ann Am Thorac Soc* 2018; 15:33-41.
53. Wang L, Liang R, Zhou T, Zheng J, Liang BM, Zhang HP, et al. Identification and validation of asthma phenotypes in Chinese population using cluster analysis. *Ann Allergy Asthma Immunol* 2017;119:324-32.
54. Hsiao H-P, Lin M-C, Wu C-C, Wang C-C, Wang T-N. Sex-specific asthma phenotypes, inflammatory patterns, and asthma control in a cluster analysis. *J Allergy Clin Immunol Pract* 2019;7:556-567.e15.
55. Lefaudeux D, De Meulder B, Loza MJ, Pepper N, Rowe A, Baribaud F, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. *J Allergy Clin Immunol* 2017;139:1797-807.
56. Kim T-B, Jang A-S, Kwon H-S, Park J-S, Chang Y-S, Cho S-H, et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. *Eur Respir J* 2013;41:1308-14.
57. Khushf RJ, Sont JK, Loijmans RJB, Snoeck-Stroband JB, Assendelft PJJ, Schermer TRJ, et al. Longitudinal outcomes of different asthma phenotypes in primary care, an observational study. *NPJ Prim Care Respir Med* 2017;27: 55.
58. Kisiel MA, Zhou X, Sundh J, Ställberg B, Lisspers K, Malinovschi A, et al. Data-driven questionnaire-based cluster analysis of asthma in Swedish adults. *NPJ Prim Care Respir Med* 2020;30:14.
59. Qiu R, Xie J, Chung KF, Li N, Yang Z, He M, et al. Asthma phenotypes defined from parameters obtained during recovery from a hospital-treated exacerbation. *J Allergy Clin Immunol Pract* 2018;6:1960-7.
60. Nadif R, Febrissy M, Andrianjafimasy MV, Le Moual N, Gormand F, Just J, et al. Endotypes identified by cluster analysis in asthmatics and non-asthmatics and their clinical characteristics at follow-up: the case-control EGEA study. *BMJ Open Respir Res* 2020;7:e000632.
61. Kaneko Y, Masuko H, Sakamoto T, Iijima H, Naito T, Yatagai Y, et al. Asthma phenotypes in Japanese adults—their associations with the CCL5 and ADRB2 genotypes. *Allergol Int* 2013;62:113-21.
62. Reddel HK, Vestbo J, Agustí A, Anderson GP, Bansal AT, Beasley R, et al. Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. *Eur Respir J* 2021;58:2003927.

63. Papi A. Asthma COPD overlap PRO-CON debate. ACO: the mistaken term. *COPD* 2020;17:474-6.
64. McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. *Eur Respir J* 2019;53:1802058.
65. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010;182:693-718.
66. To T, Zhu J, Larsen K, Simatovic J, Feldman L, Ryckman K, et al. Progression from asthma to chronic obstructive pulmonary disease. Is air pollution a risk factor? *Am J Respir Crit Care Med* 2016;194:429-38.
67. Martinez FD. Early-life origins of chronic obstructive pulmonary disease. *N Eng J Med* 2016;375:871-8.
68. Chalmers G, MacLeod K, Thomson L, Little S, McSharry C, Thomson N. Smoking and airway inflammation in patients with mild asthma. *Chest* 2001;120:1917-22.
69. Telenga E, Kerstjens H, ten Hacken N, Postma D, van den Berge M. Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. *BMC Pulm Med* 2013;13:58.
70. Broekema M, ten Hacken NHT, Volbeda F, Lodewijk ME, Hylkema MN, Postma DS, et al. Airway epithelial changes in smokers but not in ex-smokers with asthma. *Am J Respir Crit Care Med* 2009;180:1170-8.
71. Boulet L-P, Lemiere C, Archambault F, Carrier G, Descary MC, Deschesnes F. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. *Chest* 2006;129:661-8.
72. Demarche S, Schleich F, Henket M, Paulus V, Van Hees T, Louis R. Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory? *BMC Pulm Med* 2016;16:1-13.
73. Jang A, Park J, Lee J, Park S, Kim D, Uh S, et al. The impact of smoking on clinical and therapeutic effects in asthmatics. *J Korean Med Sci* 2009;24:209-14.
74. Wu D, Lai T, Yuan Y, Chen M, Xia J, Li W, et al. Elevated expression of placental growth factor is associated with airway-wall vascular remodelling and thickening in smokers with asthma. *Sci Rep* 2017;7:43017.
75. Wilson SJ, Ward JA, Sousa AR, Corfield J, Bansal AT, De Meulder B, et al. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. *Eur Respir J* 2016;48:1307-19.
76. Klein DK, Silberbrandt A, Frössing L, Hvidtfeldt M, von Bülow A, Nair P, et al. Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma. *Eur Respir J*. 2102446. Published online March 2, 2022. <https://doi.org/10.1183/13993003.02446-2021>.
77. St-Laurent J, Bergeron C, Pagé N, Couture C, Lavolette M, Boulet L. Influence of smoking on airway inflammation and remodelling in asthma. *Clin Exp Allergy* 2008;38:1582-9.
78. Kane B, Kolsum U, Southworth T, Armstrong J, Woodcock A, Singh D. The effects of smoking on the lipopolysaccharide response and glucocorticoid sensitivity of alveolar macrophages of patients with asthma. *Chest* 2009;136:163-70.
79. Tsoumakidou M, Elston W, Zhu J, Wang Z, Gamble E, Siafakas NM, et al. Cigarette smoking alters bronchial mucosal immunity in asthma. *Am J Respir Crit Care Med* 2007;175:919-25.
80. Jung YS, Park JH, Park DI, Sohn CI, Lee JM, Kim TI. Impact of smoking on human natural killer cell activity: a large cohort study. *J Cancer Prev* 2020;25:13-20.
81. Thomson NC, Chaudhuri R, Spears M, Messow CM, MacNee W, Connell M, et al. Poor symptom control is associated with reduced CT scan segmental airway lumen area in smokers with asthma. *Chest* 2015;147:735-44.
82. Boulet LP, Boulay ME, Coxson HO, Hague CJ, Milot J, Lepage J, et al. Asthma with irreversible airway obstruction in smokers and nonsmokers: links between airway inflammation and structural changes. *Respiration*. 1-11. Published online December 8, 2020. <https://doi.org/10.1159/000508163>.
83. Takahashi K, Pavlidis S, Ng Kee Kwong F, Hoda U, Rossios C, Sun K, et al. Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. *Eur Respir J* 2018;51:1702173.
84. Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. *Int J Environ Res Public Health* 2018;15:1033.
85. Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. *J Infect* 2013;67:169-84.
86. Livingston E, Darroch C, Chaudhuri R, McPhee I, McMahon A, MacKenzie S, et al. Glucocorticoid receptor alpha to beta ratio in blood mononuclear cells is reduced in cigarette smokers. *J Allergy Clin Immunol* 2004;114:1475-8.
87. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. *Annu Rev Physiol* 2009;71:451-64.
88. Ilmarinen P, Tuomisto LE, Niemelä O, Danielsson J, Haanpää J, Kankaanranta T, et al. Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma. *Eur Respir J* 2016;48:1052-62.
89. Simpson AJ, Hekking P-P, Shaw DE, Fleming LJ, Roberts G, Riley JH, et al. Treatable traits in the European U-BIOPRED adult asthma cohorts. *Allergy* 2019;74:406-11.
90. Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, et al. Relapse prevention interventions for smoking cessation. *Cochrane Database Syst Rev* 2019;2019:CD003999.
91. Tonnesen P, Pisinger C, Hvidberg S, Wenneke P, Bremann L, Westin A, et al. Effects of smoking cessation and reduction in asthmatics. *Nicotine Tob Res* 2005;7:139-48.
92. Westergaard CG, Porsbjerg C, Backer V. The effect of smoking cessation on airway inflammation in young asthma patients. *Clin Exp Allergy* 2014;44:353-61.
93. Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. *Am J Respir Crit Care Med* 2006;174:127-33.
94. Clatworthy J, Price D, Ryan D, Haughey J, Horne R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. *Prim Care Respir J* 2009;18:300-5.
95. Perret JL, Vicendese D, Simons K, Jarvis DL, Lowe AJ, Lodge CJ, et al. Ten-year prediction model for post-bronchodilator airflow obstruction and early detection of COPD: development and validation in two middle-aged population-based cohorts. *BMJ Open Respir Res* 2021;8:e001138.
96. Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. *Respir Med* 2011;105:477-84.
97. Jiménez-Ruiz CA, Andreas S, Lewis KE, Tonnesen P, van Schayck CP, Hajek P, et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. *Eur Respir J* 2015;46:61-79.
98. Polosa R, Caponnetto P, Sands MF. Caring for the smoking asthmatic patient. *J Allergy Clin Immunol* 2012;130:1221-4.
99. Leone FT, Zhang Y, Evers-Casey S, Evins AE, Eakin MN, Fathi J, et al. Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2020;202:e5-31.
100. Hajat C, Stein E, Shantikumar S, Niaura R, Ferrara P, Polosa R. A scoping review of studies on the health impact of electronic nicotine delivery systems. *Intern Emerg Med* 2022;17:241-68.
101. Polosa R, Morjaria JB, Caponnetto P, Caruso M, Campagna D, Amaradio MD, et al. Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. *Discov Med* 2016;21:99-108.
102. Hayes-Watson C, Nuss H, Tseng TS, Parada N, Yu Q, Celestin M, et al. Self-management practices of smokers with asthma and/or chronic obstructive pulmonary disease: a cross-sectional survey. *COPD Res Prac* 2017;3:3.
103. Monteiro C, Maricoto T, Prazeres F, Augusto Simões P, Augusto Simões J. Determining factors associated with inhaled therapy adherence on asthma and COPD: a systematic review and meta-analysis of the global literature. *Respir Med* 2021;191:106724.
104. Barbara SA, Kritikos V, Price DB, Bosnic-Anticevich S. Identifying patients at risk of poor asthma outcomes associated with making inhaler technique errors. *J Asthma* 2021;58:967-78.
105. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. *Thorax* 2002;57:226-30.
106. Tomlinson JEM, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. *Thorax* 2005;60:282-7.
107. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. *Am J Respir Crit Care Med* 2007;175:783-90.
108. Clearie KL, McKinlay L, Williamson PA, Lipworth BJ. Fluticasone/salmeterol combination confers benefits in people with asthma who smoke. *Chest* 2012;141:330-8.

109. Cahn A, Boyce M, Mistry S, Musani N, Rambaran C, Storey J, et al. Randomised trial of allergen-induced asthmatic response in smokers and non-smokers: effects of inhaled corticosteroids. *Clin Exp Allergy* 2015;45:1531-41.
110. Pedersen SE, Bateman ED, Bousquet J, Busse WW, Yoxall S, Clark TJ. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma Control Study. *J Allergy Clin Immunol* 2007;120:1036-42.
111. O'Byrne PM, Lamm CJ, Busse WW, Tan WC, Pedersen Sr. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. *Chest* 2009;136:1514-20.
112. Dijkstra A, Vonk JM, Jongepier H, Koppelman GH, Schouten JP, ten Hacken NHT, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. *Thorax* 2006;61:105-10.
113. Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. *Thorax* 2006;61:100-4.
114. Zheng X, Guan W, Zheng J, Ye P, Liu S, Zhou J, et al. Smoking influences response to inhaled corticosteroids in patients with asthma: a meta-analysis. *Curr Med Res Opin* 2012;28:1791-8.
115. Hayes CE, Nuss HJ, Tseng T-S, Moody-Thomas S. Use of asthma control indicators in measuring inhaled corticosteroid effectiveness in asthmatic smokers: a systematic review. *J Asthma* 2015;52:996-1005.
116. Roche N, Postma DS, Colice G, Burden A, Guilbert TW, Israel E, et al. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. *Am J Respir Crit Care Med* 2015;191:960-4.
117. Thomson NC. Challenges in the management of asthma associated with smoking-induced airway diseases. *Expert Opin Pharmacother* 2018;19:1565-79.
118. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. *Lancet Respir Med* 2019;7:745-56.
119. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med* 2018;6:117-26.
120. Bhatt SP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans Nicholas J, et al. Cigarette smoking and response to inhaled corticosteroids in COPD. *Eur Respir J* 2018;51:1701393.
121. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide—formoterol as needed in mild asthma. *N Engl J Med* 2018;378:1865-76.
122. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide—formoterol versus maintenance budesonide in mild asthma. *N Engl J Med* 2018;378:1877-87.
123. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. *N Engl J Med* 2019;380:2020-30.
124. Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRAC-TICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. *Lancet* 2019;394:919-28.
125. Thomson NC, Chaudhuri R. GINA recommendations in adults with symptomatic mild asthma and a smoking history. *Eur Respir J* 2020;55:1902043.
126. Contoli M, Bellini F, Morandi L, Forini G, Bianchi S, Gnesini G, et al. Assessing small airway impairment in mild-to-moderate smoking asthmatic patients. *Eur Respir J* 2016;47:1264-7.
127. Pilcher J, Patel M, Reddel HK, Pritchard A, Black P, Shaw D, et al. Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. *Respirology* 2016;21:858-66.
128. van Schayck OCP, Haughney J, Aubier M, Selroos O, Ekström T, Ostinelli J, et al. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. *Respir Med* 2012;106:189-96.
129. Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. *Respir Med* 2016;117:198-206.
130. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. *Respir Med* 2008;102:50-6.
131. Jabbal S, Kuo CR, Lipworth B. Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics. *Clin Exp Allergy* 2020;50:1140-7.
132. Hanania NA, Chipps BE, Griffin NM, Yoo B, Iqbal A, Casale TB. Omalizumab effectiveness in Asthma COPD overlap: post hoc analysis of PROSPERO study. *J Allergy Clin Immunol* 2019;143:1629-33.
133. Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. *Eur Respir J* 2020;56:2000151.
134. Wenzel SE, Jayawardena S, Graham NMH, Pirozzi G, Teper A. Severe asthma and asthma-chronic obstructive pulmonary disease syndrome: authors' reply. *Lancet* 2016;388:2742.
135. Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, et al. Randomised controlled trial of azithromycin in smokers with asthma. *Eur Respir J* 2013;42:1412-5.
136. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. *Lancet* 2017;390:659-68.
137. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. *Am J Respir Crit Care Med* 2014;189:1503-8.
138. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. *Am J Respir Crit Care Med* 2003;168:1308-11.
139. Livingston E, Chaudhuri R, McMahon AD, Fraser I, McSharry CP, Thomson NC. Systemic sensitivity to corticosteroids in smokers with asthma. *Eur Respir J* 2007;29:64-71.
140. Otoshi R, Baba T, Aiko N, Tabata E, Sadoyama S, Nakagawa H, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma with smoking history: a single-center experience. *Int Arch Allergy Immunol* 2020;181:522-8.
141. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RFT, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. *N Engl J Med* 2011;364:1695-707.
142. Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, et al. Effect of montelukast for treatment of asthma in cigarette smokers. *J Allergy Clin Immunol* 2013;131:763-71.
143. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2019;5:CD001287.
144. Thomson NC, Charron CE, Chaudhuri R, Spears M, Ito K, McSharry C. Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. *Pulm Pharmacol Ther* 2015;31:1-8.
145. Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, et al. Effects of short-term treatment with atorvastatin in smokers with asthma—a randomized controlled trial. *BMC Pulm Med* 2011;11:16.
146. Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. *Eur Respir J* 2009;33:1010-7.
147. Thomson NC, Chaudhuri R, Spears M, Haughney J, McSharry C. Serum periostin in smokers and never smokers with asthma. *Respir Med* 2015;109:708-15.
148. Shantakumar S, Ho YF, Beale J, Gribben B. Characterization and burden of severe eosinophilic asthma in New Zealand: results from the HealthStat database. *Multidiscip Respir Med* 2020;15:662.
149. Tsiavia T, Henny J, Goldberg M, Zins M, Roche N, Orsi L, et al. Blood inflammatory phenotypes were associated with distinct clinical expressions of asthma in adults from a large population-based cohort. *EBioMedicine* 2022;76:103875.
150. Papatheanasiou E, Bakakos P, Hillas G, Ntontsi P, Blizou M, Kostikas K, et al. Diagnostic accuracy of T2 biomarkers for the prediction of airway eosinophilia in treated smoking asthmatics with loss of asthma control. *J Allergy Clin Immunol Pract* 2020;8:385-7.
151. Jarvis D, Chinn S, Lucynska C, Burney P. The association of smoking with sensitization to common environmental allergens: results from the European Community Health Survey. *J Allergy Clin Immunol* 1999;104:934-40.
152. Mónico B, Gama JMR, Pastorinho MR, Lourenço O. Tobacco smoke as a risk factor for allergic sensitization in adults: conclusions of a systematic review and meta-analysis. *J Allergy Clin Immunol* 2019;143:417-9.

153. Brown T, Jones T, Gove K, Barber C, Elliott S, Chauhan A, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. *Eur Respir J* 2018;52:1801444.
154. Han YY, Zhang X, Wang J, Wang G, Oliver BG, Zhang HP, et al. Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study. *J Allergy Clin Immunol Pract* 2021;9:349-362.e18.
155. Kerkhof M, Tran TN, Allehebi R, Canonica GW, Heaney LG, Hew M, et al. Asthma phenotyping in primary care: applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities. *J Allergy Clin Immunol Pract* 2021;9:4353-70.
156. Jo YS, Hwang YI, Yoo KH, Kim TH, Lee MG, Lee SH, et al. Effect of inhaled corticosteroids on exacerbation of asthma-COPD overlap according to different diagnostic criteria. *J Allergy Clin Immunol Pract* 2020;8:1625-1633.e6.
157. Ricciardolo FLM, Sprio AE, Baroso A, Gallo F, Riccardi E, Bertolini F, et al. Characterization of T2-low and T2-high asthma phenotypes in real-life. *Biomedicines* 2021;9:1684.